Gilead reported second-quarter earnings that exceeded expectations and subsequently raised its financial outlook for the full year 2025. This positive performance drove the company's stock price up over 7%. The strong results were attributed to gains in its HIV portfolio, the strength of its cancer drug Trodelvy, and the successful launch of its new PrEP medication, Yeztugo.